Emodepside has demonstrated anthelmintic activity in studies conducted in sheep, cattle, horses, and dogs directed against trichostrongyles, roundworms, hookworms, whipworms, large and small strongyles, and lungworms. Emodepside has been shown to possess resistance-breaking properties against certain ivermectin-, benzimidazole-, and levamisole-resistant nematode strains in sheep and an ivermectin-resistant nematode isolate in cattle. Emodepside is currently available in some countries in combination with praziquantel (for treatment of cestode infections) as a topical formulation (3 mg/kg) for the treatment of ascarids and hookworms in cats (including larval stages) and as an oral formulation (1 mg/kg) for the treatment of ascarids, hookworms, and Trichuris in dogs (including larval stages). For dogs, emodepside is also available in combination with toltrazuril as an oral suspension for coccidia and GI nematode control.
